GRI 1

Drug Profile

GRI 1

Latest Information Update: 03 Mar 2008

Price : $50

At a glance

  • Originator NPS Pharmaceuticals
  • Developer Janssen L.P.; NPS Pharmaceuticals
  • Class Antipsychotics
  • Mechanism of Action Glycine reuptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Dementia; Schizophrenia

Most Recent Events

  • 09 Dec 2005 Phase-I clinical trials in Schizophrenia in USA (unspecified route)
  • 20 Oct 2003 Preclinical trials in Dementia in USA (unspecified route)
  • 19 Nov 2001 NPS Pharmaceuticals has received a milestone payment from Janssen in recognition of selection of a promising drug candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top